Keyphrases
Advanced Solid Tumors
100%
Ridaforolimus
100%
Phase 1 Trial
100%
MK-0752
100%
Maximum Tolerated Dose
37%
Dose-limiting Toxicity
37%
Stomatitis
37%
PI3K Pathway
25%
Diarrhea
25%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
25%
Asthenia
25%
Cell Growth
12%
Dose-escalation Study
12%
Dose Escalation
12%
Cell Proliferation
12%
Solid Tumors
12%
Hyperglycemia
12%
Clinical Development
12%
MTOR Inhibitor
12%
Thrombocytopenia
12%
Stable Disease
12%
Rash
12%
Once-weekly
12%
Adverse Events
12%
Complete Response
12%
Partial Response
12%
Decreased Appetite
12%
Notch Signaling
12%
Cell Metabolism
12%
Drug Adverse Events
12%
PI3K-AKT-mTOR Pathway
12%
Toxicity Grades
12%
Notch Inhibitor
12%
One Dose
12%
Second Episode
12%
Intra-patient
12%
Mechanistic Target of Rapamycin Kinase
12%
Medicine and Dentistry
Solid Malignant Neoplasm
100%
Ridaforolimus
100%
Stomatitis
37%
Adverse Event
25%
Head and Neck Squamous Cell Carcinoma
25%
Diarrhea
25%
Asthenia
25%
Malignant Neoplasm
12%
Cell Growth
12%
Disease
12%
mTOR Signaling
12%
Notch
12%
Cell Proliferation
12%
Exanthem
12%
Hyperglycemia
12%
Cell Metabolism
12%
Phosphoinositide 3-Kinase
12%
Thrombocytopenia
12%
Decreased Appetite
12%
Mechanistic Target of Rapamycin
12%
Mammalian Target of Rapamycin Inhibitor
12%
Signal Transduction
12%
Protein Kinase B
12%
Notch Signaling
12%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Ridaforolimus
100%
Stomatitis
37%
Maximum Tolerated Dose
37%
Diarrhea
25%
Adverse Event
25%
Asthenia
25%
Head and Neck Squamous Cell Carcinoma
25%
Malignant Neoplasm
12%
Mammalian Target of Rapamycin Inhibitor
12%
Phosphatidylinositol 3 Kinase
12%
Rash
12%
Decreased Appetite
12%
Disease
12%
Thrombocytopenia
12%
Protein Kinase B
12%
Hyperglycemia
12%
Mammalian Target of Rapamycin
12%